Pentadecapeptide BPC 157 Counteracts Hemodynamic and ECG Disturbances Induced by Sotalol in Rats - Premuzic Mestrovic - 2022 - The FASEB Journal - Wiley Online Library
Volume 36, Issue S1
Pharmacology
Free Access

Pentadecapeptide BPC 157 Counteracts Hemodynamic and ECG Disturbances Induced by Sotalol in Rats

Ivica Premuzic Mestrovic

Ivica Premuzic Mestrovic

Cardiology, Clinical Hospital “Merkur”, Zagreb

Search for more papers by this author
Ivan Maria Smoday

Ivan Maria Smoday

Pharmacology, School of Medicine University of Zagreb, Zagreb

Search for more papers by this author
Tomislav Mestrovic

Tomislav Mestrovic

Vascular surgery, University Hospital Centre Zagreb, Zagreb

Search for more papers by this author
Helena Zizek

Helena Zizek

Pharmacology, School of Medicine University of Zagreb, Zagreb

Search for more papers by this author
Anita Skrtic

Anita Skrtic

Pathology, School of Medicine University of Zagreb, Zagreb

Search for more papers by this author
Ivan Skorak

Ivan Skorak

Vascular surgery, University Hospital Centre Zagreb, Zagreb

Search for more papers by this author
Damir Haluzan

Damir Haluzan

Vascular surgery, University Hospital Centre Zagreb, Zagreb

Search for more papers by this author
Josip Figl

Josip Figl

Vascular surgery, University Hospital Centre Zagreb, Zagreb

Search for more papers by this author
Ivan Brizic

Ivan Brizic

Vascular surgery, University Hospital Centre Zagreb, Zagreb

Search for more papers by this author
Mario Staresinic

Mario Staresinic

Vascular surgery, University Hospital Centre Zagreb, Zagreb

Search for more papers by this author
Predrag Pavic

Predrag Pavic

Vascular surgery, University Hospital Centre Zagreb, Zagreb

Search for more papers by this author
Sven Seiwerth

Sven Seiwerth

Pathology, School of Medicine University of Zagreb, Zagreb

Search for more papers by this author
Predrag Sikiric

Predrag Sikiric

Pathology, School of Medicine University of Zagreb, Zagreb

Search for more papers by this author
University of Zagreb Grant number 099

Abstract

Cytoprotective and organoprotective pentadecapeptide BPC 157 demonstrated particular beneficial cardiovascular effects (Curr Pharm Des. 2014;20(7):1121-1125). Antiarrhythmic effects counteracted digoxin toxicity (Regul Pept. 2009;156(1-3):83-89), major blood vessel occlusions (Biomedicines 2021, 9,1029; 2021, 9,609; 2021, 9, 792) and lidocaine toxicity (Emerg Med Int. 2020;2020:6805354). Now, we reveal, by BPC 157, mitigation of hemodynamic and ECG disturbances of sotalol, a class III antiarrhythmic with non-selective beta-blocking activity.

Albino Wistar rats received sotalol (80mg/kg, intragastrically), and at 5 min thereafter were treated with saline or BPC 157 (10ng/kg, intragastrically. Seven standard and one precordial ECG leads were recorded (baseline; after application of sotalol; and 10, 30, 90, 120 and 150 minutes after application of sotalol). Heart rate, QRS complex, PR and QT intervals were analyzed. Corrected QT intervals (QTc) were calculated according to Fridericia formula.

Baseline ECG readings included average heart rate of 275.5 ± 25 bpm, average PR 54.8 ± 3.4 ms, average QRS complex 25.0 ± 4.23 ms and average QTc 166 ± 9.7 ms. Sotalol caused bradycardia (245 ± 23.5 bpm), PR prolongation (57.3 ± 2.7 ms), QRS widening (26.3 ± 3.2 ms), and QTc prolongation (173 ± 9.1 ms), measured 10 minutes after application. In BPC 157 treated animals (5 minutes after BPC-157 application, 10 minutes after sotalol application), these effects were attenuated (heart rate 306 ± 31.7 bpm, average PR 52.3 ± 1.6 ms, average QRS 23.7 ± 5.4 ms and average QTc 159 ± 21.2 ms). This attenuation was lost in later measurements, for QRS - 25 minutes after BPC 157 application, for frequency after 55 minutes, for PR after 115 minutes and for QTc after 145 minutes. In animals treated with sotalol, an increase in superior sagittal sinus pressure (10 ± 5 mmHg), as well as an increase in portal vein (17 ± 4 mmHg) and inferior caval vein pressures (12 ± 6 mmHg) were noted, along with the decrease in abdominal aortic pressure (53 ± 10 mmHg). These effects were attenuated in BPC treated animals (-1 ± 1 mmHg for superior sagittal sinus, 7 ± 1 mmHg in portal vein, 5 ± 1 mmHg in inferior caval vein, and 81 ± 7 mmHg in abdominal aorta).

In conclusion, BPC 157 attenuated deleterious hemodynamic effects of sotalol while the effects on the ECG parameters were also noted, although not long lasting, supporting the view of BPC-157 as a rapid-acting protective agent.

This is the full abstract presented at the Experimental Biology meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract.